Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7526068 | 0.78 | CYP1A2 (0.41) | MEN1ALDH1A1LMNAALOX12KMT2A | |
| SCHEMBL10387752 | 0.78 | CYP1A2 (0.41) | MEN1ALDH1A1LMNAALOX12KMT2A | |
| SCHEMBL11094087 | 0.77 | CHRM2 (0.32) | MEN1ALDH1A1LMNAALOX12KMT2A | |
| SCHEMBL25418137 | 0.76 | MEN1 (0.36) | MEN1ALDH1A1LMNAALOX12KMT2A | |
| SCHEMBL1930395 | 0.76 | CYP1A2 (0.44) | MEN1ALDH1A1LMNAALOX12KMT2A | |
| SCHEMBL2777672 | 0.76 | MEN1 (0.40) | MEN1ALDH1A1LMNAALOX12KMT2A | |
| SCHEMBL18729659 | 0.76 | — | — | |
| SCHEMBL20350217 | 0.75 | CYP1A2 (0.37) | MEN1ALDH1A1LMNAALOX12KMT2A | |
| SCHEMBL2994447 | 0.74 | MEN1 (0.40) | MEN1ALDH1A1LMNAALOX12KMT2A | |
| SCHEMBL11697439 | 0.73 | CYP1A2 (0.52) | MEN1ALDH1A1LMNAALOX12KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6958402-B2 | 3-(imidazolyl)-2-alkoxypropanoic acids | PFIZER, INC. (US) | 2005-10-25 | — | — | US | disclosed |
| CN-1620291-A | 3-(imidazolyl)-2-alkoxypropanoic acids as TAFIA inhibitors | PFIZER (US) | 2005-05-25 | — | — | CN | disclosed |
| US-20040254164-A1 | 3-(imidazolyl)-2-alkoxypropanoic acids | PFIZER INC. (US) | 2004-12-16 | — | — | US | disclosed |
| US-6713496-B2 | 3-(imidazolyl)-2-alkoxypropanoic acids | PFIZER INC | 2004-03-30 | — | — | US | disclosed |
| US-20030199522-A1 | 3-(Imidazolyl)-2-alkoxypropanoic acids | PFIZER INC. | 2003-10-23 | — | — | US | disclosed |
| WO-2003061652-A1 | 3-(IMIDAZOLYL)-2-ALKOXYPROPANOIC ACIDS AS TAFIA INHIBITORS | PFIZER LIMITED (GB) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199522-A1 | 3-(Imidazolyl)-2-alkoxypropanoic acids | F2, FGB, F7 | MEN1 1716/4885ALDH1A1 191/4885LMNA 1149/4885 |
| US-20040254164-A1 | 3-(imidazolyl)-2-alkoxypropanoic acids | F2, FGB, F7 | MEN1 1756/4885ALDH1A1 217/4885LMNA 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.